Nkarta, Inc., a clinical-stage biotech company developing engineered natural killer (NK) cell therapies for autoimmune diseases, announced it will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. Nkarta's President Nadir Mahmood will discuss updates on their investigational CAR-NK cell therapy targeting B cell-mediated autoimmune diseases. The presentation will be webcast live and available for replay on Nkarta's website. This event highlights Nkarta's progress in advancing off-the-shelf NK cell therapies designed for outpatient use, potentially broadening patient access to innovative autoimmune treatments in community health settings.
Cate & Chloe is participating in Walmart's Summer Deals Event from June 22 to June 28, offering its Eden 18k White Gold Plated Crystal Stud Earrings at a discounted price of $16.99, down from $77. This sale highlights the brand's focus on affordable ...
The global protein ingredients market is projected to grow from $83.14 billion in 2026 to $121.53 billion by 2031, at a CAGR of 7.9%. Growth is fueled by rising consumer demand for functional and high-protein foods, increased awareness of protein's h...
UBS Group AG has increased its stake in Bang & Olufsen A/S to 5.07% of the total share capital and voting rights as of June 23, 2026, holding 7,473,135 shares. This change follows a previous holding below 5% on June 22, 2026, marking UBS as a major s...
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now accessible on-demand for 90 days. This event featured multiple life sciences companies presenting to investors, with opportunit...
Vaxart, a clinical-stage biotech company, has published a presentation urging shareholders to vote for all six of its director nominees at the upcoming Annual Meeting. The company highlights its progress in developing oral vaccines for COVID-19, noro...
